Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:TEK NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTEKiShares Technology Opportunities Active ETF$28.69-2.2%$28.21$19.03▼$29.79$24.10MN/A9,099 shs6,576 shsTERNTerns Pharmaceuticals$6.55-3.1%$5.11$1.87▼$11.40$591.58M-0.051.11 million shs1.43 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTEKiShares Technology Opportunities Active ETF+0.14%+0.48%+2.62%+14.56%+2,934,999,900.00%TERNTerns Pharmaceuticals-4.11%+7.30%+19.86%+114.60%-6.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationTEKiShares Technology Opportunities Active ETFN/AN/AN/AN/AN/AN/AN/AN/ATERNTerns Pharmaceuticals3.7372 of 5 stars3.31.00.04.11.83.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTEKiShares Technology Opportunities Active ETF 2.88Moderate Buy$28.69N/ATERNTerns Pharmaceuticals 2.60Moderate Buy$15.63138.55% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTEKiShares Technology Opportunities Active ETFN/AN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$3.49 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTEKiShares Technology Opportunities Active ETFN/AN/A43.98∞N/AN/AN/AN/AN/ATERNTerns Pharmaceuticals-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%N/ALatest TERN, TEK, LBOW, and TPVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025TERNTerns Pharmaceuticals-$0.28-$0.26+$0.02-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthTEKiShares Technology Opportunities Active ETFN/A0.03%N/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTEKiShares Technology Opportunities Active ETFN/AN/AN/ATERNTerns PharmaceuticalsN/A24.7024.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTEKiShares Technology Opportunities Active ETFN/ATERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipTEKiShares Technology Opportunities Active ETFN/ATERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableTEKiShares Technology Opportunities Active ETFN/A840,000N/AN/ATERNTerns Pharmaceuticals4087.51 million86.20 millionNot OptionableTERN, TEK, LBOW, and TPVE HeadlinesRecent News About These Companies5 Oral Obesity Drugs Challenging Lilly’s OrforglipronAugust 12, 2025 | biospace.comBWilliam Blair Has Positive Outlook of TERN FY2025 EarningsAugust 9, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPSAugust 6, 2025 | marketbeat.comTerns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity MarketAugust 6, 2025 | biospace.comBTerns to stop funding metabolic disease trials beyond 2025, seeks partners for assetsAugust 6, 2025 | fiercebiotech.comFTerns (TERN) Q2 Net Loss Narrows 16%August 6, 2025 | fool.comTerns Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 6, 2025 | tipranks.comTerns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 5, 2025 | globenewswire.comTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)August 4, 2025 | globenewswire.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 3, 2025 | marketbeat.comTerns Pharmaceuticals (TERN) to Release Quarterly Earnings on MondayJuly 28, 2025 | marketbeat.comObesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-WaitingJuly 14, 2025 | biospace.comBTerns Pharmaceuticals CEO & Director Acquires 98% More StockJuly 4, 2025 | finance.yahoo.comTerns pharmaceuticals CEO Burroughs buys $90k in sharesJune 27, 2025 | investing.comRivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potentialJune 26, 2025 | fiercebiotech.comFTerns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - NasdaqJune 24, 2025 | nasdaq.comTerns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - MorningstarJune 24, 2025 | morningstar.comMNovel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly DosingJune 23, 2025 | medpagetoday.comMTerns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific SessionsJune 23, 2025 | globenewswire.comPopulation-Level Weight Loss Seen With Primary Care ProtocolJune 21, 2025 | medscape.comMTerns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Buys $19,750.00 in StockJune 17, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRigetti Soars 30% on Latest Quantum Leap: What It Means Long-TermBy Leo Miller | July 22, 2025How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?By Jordan Chussler | August 14, 2025Tesla Is Balanced on a Knife Edge: Time to Tread CarefullyBy Sam Quirke | August 8, 2025Why Freeport-McMoRan Stock May Hit a New High After Earnings BeatBy Chris Markoch | July 25, 2025Global Value: 3 Stocks Under $10 Riding a Weak DollarBy Chris Markoch | July 30, 2025TERN, TEK, LBOW, and TPVE Company DescriptionsiShares Technology Opportunities Active ETF NYSEARCA:TEK$28.69 -0.66 (-2.25%) As of 04:10 PM EasternThe iShares Technology Opportunities Active ETF (TEK) is an exchange-traded fund that mostly invests in information technology equity. The fund is actively managed, investing in US and non-US technology companies across all market capitalizations. The fund aims for long-term growth of capital, focusing on firms with rapid growth potential in the industry TEK was launched on Oct 21, 2024 and is issued by BlackRock.Terns Pharmaceuticals NASDAQ:TERN$6.55 -0.21 (-3.11%) Closing price 04:00 PM EasternExtended Trading$6.51 -0.04 (-0.61%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Home Depot Holds Gains After Narrow Q2 Misses Medtronic: The Opportunity Gets Healthier for Income Investors Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s End Micron Stock Still Cheap Despite 25% Rally, Analysts Say Qualcomm Just Passed 1 Major Test, But Can It Pass the Next? DLocal Stock Soars 43% After Earnings Beat and Raised Guidance D-Wave Buying Spree: Will These Firms Be Potential Targets? Lyft's Billion-Dollar Signal: Why Wall Street Is Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access